Literature DB >> 2685050

Evaluation of commercial latex slide test for identifying Escherichia coli O157.

P A Chapman1.   

Abstract

A commercial latex slide test (Oxoid DR 620) for the identification of Escherichia coli O157 was compared with a standard tube agglutination method using E coli O157 antiserum (Difco). Thirty isolates previously confirmed as E coli O157 were positive by both methods: 30 isolates of E coli of serogroups other than O157, 30 isolates of non-sorbitol fermenting organisms from various genera, and one isolate of E hermanii were all negative by both methods. It is concluded that the latex slide test offers a rapid and economical alternative to tube agglutination for the identification of E coli O157.

Entities:  

Mesh:

Year:  1989        PMID: 2685050      PMCID: PMC501874          DOI: 10.1136/jcp.42.10.1109

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  Properties of an Escherichia coli cytotoxin.

Authors:  J Konowalchuk; N Dickie; S Stavric; J I Speirs
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

2.  False positive identifications of Escherichia coli O157.

Authors:  H Lior; A A Borczyk
Journal:  Lancet       Date:  1987-02-07       Impact factor: 79.321

3.  Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7. Clinical, epidemiologic, and bacteriologic features.

Authors:  C H Pai; R Gordon; H V Sims; L E Bryan
Journal:  Ann Intern Med       Date:  1984-12       Impact factor: 25.391

4.  Haemorrhagic colitis and Vero-cytotoxin-producing Escherichia coli in England and Wales.

Authors:  H R Smith; B Rowe; R J Gross; N K Fry; S M Scotland
Journal:  Lancet       Date:  1987-05-09       Impact factor: 79.321

5.  Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis.

Authors:  S B March; S Ratnam
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

6.  Vero cytotoxin-producing strains of Escherichia coli from children with haemolytic uraemic syndrome and their detection by specific DNA probes.

Authors:  S M Scotland; B Rowe; H R Smith; G A Willshaw; R J Gross
Journal:  J Med Microbiol       Date:  1988-04       Impact factor: 2.472

7.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

8.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

9.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

10.  A two-year survey of the incidence of heat-labile enterotoxin-producing Escherichia coli and other enteric pathogens in travellers returning to the Sheffield area.

Authors:  P A Chapman; D L Mitchelmore
Journal:  Epidemiol Infect       Date:  1988-10       Impact factor: 2.451

View more
  3 in total

1.  Immunomagnetic separation as a sensitive method for isolating Escherichia coli O157 from food samples.

Authors:  D J Wright; P A Chapman; C A Siddons
Journal:  Epidemiol Infect       Date:  1994-08       Impact factor: 2.451

2.  Cattle as a possible source of verocytotoxin-producing Escherichia coli O157 infections in man.

Authors:  P A Chapman; C A Siddons; D J Wright; P Norman; J Fox; E Crick
Journal:  Epidemiol Infect       Date:  1993-12       Impact factor: 2.451

3.  Escherichia coli O157 exposure in Wyoming and Seattle: serologic evidence of rural risk.

Authors:  Jason P Haack; Srdjan Jelacic; Thomas E Besser; Edward Weinberger; Donald J Kirk; Garry L McKee; Shannon M Harrison; Karl J Musgrave; Gayle Miller; Thomas H Price; Philip I Tarr
Journal:  Emerg Infect Dis       Date:  2003-10       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.